Ast J 2007, 13(six):551?56. 16. Jee KJ, Gong G, Ahn SH, Park JM, Knuutila

From
Jump to: navigation, search

J Pathol 2008, 214(5):533?44. 20. Perot G, Chibon F, Montero A, Lagarde P, De The H, Terrier P, Guillou L, Ranchere D, Coindre JM, Aurias A: Continual p53 pathway inactivation in aJardim et al. Orphanet Icance was defined as *p 0.05 (not important Journal of Uncommon Ailments 2013, eight:112 http://www.ojrd.com/content/8/1/Page 8 of21.22.23. 24.25.26.27. 28.29.30.31.substantial series of soft tissue sarcomas with complicated genetics. Am J Pathol 2010, 177(four):2080?090. Gatalica Z, Finkelstein S, Lucio E, Tawfik O, Palazzo J, Hightower B, Eyzaguirre E: p53 protein expression and gene mutation in phyllodes tumors in the breast. Pathol Res Pract 2001, 197(three):183?87. Korcheva VB, Levine J, Beadling C, Warrick A, Countryman G, Olson NR, Heinrich MC, Corless CL, Troxell ML: Immunohistochemical and molecular markers in breast phyllodes tumors. Appl Immunohistochem Mol Morphol: AIMM/official publication on the Society for Appl Immunohistochem 2011, 19(two):119?25. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D: RAS PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/25681438 oncogenes: weaving a tumorigenic net. Nat Rev Cancer 2011, 11(11):761?74. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, Van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A: MEK162 for patients with sophisticated melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013, 14:249?56. Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, et al: Combined targeting of MEK and PI3K/mTOR effector pathways is essential to efficiently inhibit NRAS mutant melanoma in vitro and in vivo. In Proceedings from the National Academy of Sciences with the Usa of America. ; 2013. Kulkarni SA, Hicks DG, PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/29069523 Watroba NL, Murekeyisoni C, Hwang H, Khoury T, Beck RA, Ring BZ, Estopinal NC, Schreeder MT, et al: TLE3 as a candidate biomarker of response to taxane therapy. Breast cancer res: BCR 2009, 11(2):R17. Gradishar WJ: Albumin-bound paclitaxel: a next-generation taxane. Specialist Opin Pharmacother 2006, 7(eight):1041?053. Desai N, Trieu V, Damascelli B, Soon-Shiong P: SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol 2009, 2(two):59?4. Tse GM, Lee CS, Kung FY, Scolyer RA, Law BK, Lau TS, Putti TC: Hormonal receptors expression in epithelial cells of mammary phyllodes tumors correlates with pathologic grade with the tumor: a multicenter study of 143 circumstances. Am J Clin Pathol 2002, 118(4):522?26. Feakins RM, Wells CA, Young KA, Sheaff MT: Platelet-derived growth aspect expression in phyllodes tu.Ast J 2007, 13(six):551?56. 16. Jee KJ, Gong G, Ahn SH, Park JM, Knuutila S: Get in 1q is often a prevalent abnormality in phyllodes tumours from the breast. Anal cell pathol: J Euro Society for Anal Cell Pathol 2003, 25(two):89?three. 17. Lu YJ, Birdsall S, Osin P, Gusterson B, Shipley J: Phyllodes tumors of your breast analyzed by comparative genomic hybridization and association of increased 1q copy number with stromal overgrowth and recurrence. Genes Chromosomes Cancer 1997, 20(three):275?81.